Filed - Glenmark

India Formulations
Moving forward, the plan…
Grow revenues by 15% p.a. - revised upwards from earlier guidance of 10%
Strengthen presence in respiratory, pain management and metabolic diseases
– in preparation for own NCE launches
Grow mass-market division, Milieus, through increased product launches,
sales force hires and geographic expansion
Increase in-licensing efforts for novel products to augment own pipeline
Continue launching differentiated branded generics; focus on building
power brands
Improve cost-efficiencies and cash-cycle management
Expect to Exceed April (Profit) Guidance for FY07
23